cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma.

Berberich, Anne; Schmitt, Lara-Marie; Pusch, Stefan; Hielscher, Thomas; Rübmann, Petra; Hucke, Nanina; Latzer, Pauline; Heßling, Bernd; Lemke, Dieter; Kessler, Tobias; Platten, Michael; Wick, Wolfgang

Berberich, Anne; Schmitt, Lara-Marie; Pusch, Stefan; Hielscher, Thomas; Rübmann, Petra; Hucke, Nanina; Latzer, Pauline; Heßling, Bernd; Lemke, Dieter; Kessler, Tobias; Platten, Michael; Wick, Wolfgang.

Afiliação

Berberich A; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Schmitt LM; Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Pusch S; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Hielscher T; Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Rübmann P; Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Hucke N; Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.
Latzer P; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heßling B; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Lemke D; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Kessler T; Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Platten M; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Wick W; Genomics and Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany.

J Neurooncol ; 146(1): 9-23, 2020 Jan.

Article em En | MEDLINE | ID: mdl-31776900

Assuntos

Quinase do Linfoma Anaplásico/antagonistas & inibidores; Carbazóis/farmacologia; Resistencia a Medicamentos Antineoplásicos; Glioblastoma/patologia; Proteína Quinase 1 Ativada por Mitógeno/metabolismo; Proteína Quinase 3 Ativada por Mitógeno/metabolismo; Piperidinas/farmacologia; Proteínas Proto-Oncogênicas c-myc/metabolismo; Quinase do Linfoma Anaplásico/genética; Apoptose; Biomarcadores Tumorais/genética; Biomarcadores Tumorais/metabolismo; Proliferação de Células; Regulação Neoplásica da Expressão Gênica; Glioblastoma/tratamento farmacológico; Glioblastoma/genética; Glioblastoma/metabolismo; Humanos; Proteína Quinase 1 Ativada por Mitógeno/genética; Proteína Quinase 3 Ativada por Mitógeno/genética; Mutação; Inibidores de Proteínas Quinases/farmacologia; Proteínas Proto-Oncogênicas c-myc/genética; Células Tumorais Cultivadas

Palavras-chave

Alectinib; Anaplastic lymphoma kinase; Biomarker; Glioblastoma; Treatment resistance

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperidinas / Carbazóis / Proteínas Proto-Oncogênicas c-myc / Glioblastoma / Resistencia a Medicamentos Antineoplásicos / Proteína Quinase 1 Ativada por Mitógeno / Proteína Quinase 3 Ativada por Mitógeno / Quinase do Linfoma Anaplásico Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google